Last reviewed · How we verify
Free [Per/Ind + Aml]
Free [Per/Ind + Aml] is a ACE inhibitor and calcium channel blocker combination Small molecule drug developed by Institut de Recherches Internationales Servier. It is currently in Phase 3 development for Hypertension.
A fixed-dose combination of perindopril (ACE inhibitor) and amlodipine (calcium channel blocker) that reduces blood pressure through dual vasodilation and renin-angiotensin system inhibition.
There is limited information available on the modality of Free [Per/Ind + Aml] due to unknown data on ChEMBL.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Free [Per/Ind + Aml] |
|---|---|
| Sponsor | Institut de Recherches Internationales Servier |
| Drug class | ACE inhibitor and calcium channel blocker combination |
| Target | ACE (angiotensin-converting enzyme) and L-type voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Perindopril inhibits angiotensin-converting enzyme, preventing formation of angiotensin II and reducing vasoconstriction and aldosterone secretion. Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing direct vasodilation. Together, these complementary mechanisms provide synergistic blood pressure reduction with improved tolerability compared to monotherapy.
Approved indications
- Hypertension
Common side effects
- Cough
- Peripheral edema
- Dizziness
- Headache
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Free [Per/Ind + Aml] CI brief — competitive landscape report
- Free [Per/Ind + Aml] updates RSS · CI watch RSS
- Institut de Recherches Internationales Servier portfolio CI
Frequently asked questions about Free [Per/Ind + Aml]
What is Free [Per/Ind + Aml]?
How does Free [Per/Ind + Aml] work?
What is Free [Per/Ind + Aml] used for?
Who makes Free [Per/Ind + Aml]?
What drug class is Free [Per/Ind + Aml] in?
What development phase is Free [Per/Ind + Aml] in?
What are the side effects of Free [Per/Ind + Aml]?
What does Free [Per/Ind + Aml] target?
Related
- Drug class: All ACE inhibitor and calcium channel blocker combination drugs
- Target: All drugs targeting ACE (angiotensin-converting enzyme) and L-type voltage-gated calcium channels
- Manufacturer: Institut de Recherches Internationales Servier — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing